Centiva Capital’s Organogenesis Holdings ORGO Stock Holding History

Centiva Capital’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,595	Closed	-$61.7K	–	1980
2023 Q2	$61.7K	Buy	+18,595	New	+$55K	﹤0.01%	1497

Other funds holding ORGO

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Centiva Capital's ORGO Position: Q3 2023 in Review

Centiva Capital sold out of Organogenesis Holdings (ORGO) in Q3 2023, closing a stake of 18,595 shares — an estimated $61.7K sold.

Centiva Capital first reported a position in ORGO in Q2 2023 and held it in 1 quarter. The position peaked at $61.7K in Q2 2023. 104 funds tracked by Wall St. Rank hold ORGO as of Q3 2023.

Centiva Capital reported no remaining Organogenesis Holdings position as of Q3 2023 after selling out during the quarter.
Centiva Capital sold 18,595 Organogenesis Holdings shares in Q3 2023, an estimated $61.7K.
Centiva Capital first reported a position in Organogenesis Holdings in Q2 2023 and held it in 1 quarter.
Centiva Capital's Organogenesis Holdings position peaked at $61.7K in Q2 2023.
104 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q3 2023.

Based on Centiva Capital's 13F filing for Q3 2023, filed 14 Nov 2023.